ICI15 presentation is now available

April 3, 20154-1BB, CD27, GITR, IDO, ipilimumab, News, nivolumab, oncology, OX40, PD-1, pembrolizumab, T regulatory cells, TGFbeta, TIGIT, TIM-3, TNF receptors, tumor microenvironmentPaul Rennert

The SugarCone Blog is brought to you by SugarCone Biotech Consulting - Click to learn more about what we can do for your company.

Over 100 slides on immune checkpoint combination therapy, novel targets and drug development in immuno-oncology, created for a 3 hour workshop at ICI15 (link).

As always we work from indications to discovery and back again, keeping one eye on the rapid evolution of clinical practice in oncology and the other on novel targets and therapeutics.

on SlideShare now:

The immune checkpoint landscape in 2015: combination therapy from Paul D. Rennert

Leave a comment or email us at rennertp@sugarconebiotech.com or info@sugarconebiotech.com, and follow @PDRennert on Twitter. Click to learn more about what SugarCone Biotech Consulting can do for your company. Cancel reply

You must be logged in to post a comment.